MarketPulse

Phase 1b study

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agomab Secures U.S. Patent for IPF Treatment AGMB-447 Through 2041

Agomab Therapeutics gains patent protection for AGMB-447, an inhaled lung-targeted therapy for idiopathic pulmonary fibrosis, with Phase 1b results expected in 2026.
AGMBintellectual propertyPhase 1b study
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cocrystal Pharma to Present Phase 1 Data for Oral Norovirus Treatment at ICAR 2026

Cocrystal Pharma will present Phase 1 data for oral norovirus treatment CDI-988 at 2026 conference, marking progress for first oral antiviral targeting this virus.
COCPnorovirusprotease inhibitor